Rigel Pharmaceuticals Net Profit Margin Growth & History (RIGL)
Rigel Pharmaceuticals's net profit margin was 124.72% for fiscal 2025.
View full Rigel Pharmaceuticals company overviewRigel Pharmaceuticals annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 124.72% | +114.97 pp |
| 2024 | 2024-12-31 | 9.75% | +31.22 pp |
| 2023 | 2023-12-31 | −21.47% | +27.25 pp |
| 2022 | 2022-12-31 | −48.71% | −36.71 pp |
| 2021 | 2021-12-31 | −12.00% | +15.38 pp |
| 2020 | 2020-12-31 | −27.38% | +85.45 pp |
| 2019 | 2019-12-31 | −112.83% | +45.52 pp |
| 2018 | 2018-12-31 | −158.35% | +1580.99 pp |
| 2017 | 2017-12-31 | −1,739.34% | −1399.76 pp |
| 2016 | 2016-12-31 | −339.58% | −161.47 pp |
| 2015 | 2015-12-31 | −178.11% | — |
Rigel Pharmaceuticals quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.97% | −36.66 pp |
| Q1 2026 | 2026-03-31 | 14.71% | −6.75 pp |
| Q4 2025 | 2025-12-31 | 384.04% | +359.14 pp |
| Q3 2025 | 2025-09-30 | 40.17% | +17.71 pp |
| Q2 2025 | 2025-06-30 | 58.63% | +61.42 pp |
| Q1 2025 | 2025-03-31 | 21.46% | +49.39 pp |
| Q4 2024 | 2024-12-31 | 24.90% | +22.84 pp |
| Q3 2024 | 2024-09-30 | 22.46% | +42.69 pp |
| Q2 2024 | 2024-06-30 | −2.80% | +21.75 pp |
| Q1 2024 | 2024-03-31 | −27.92% | +24.00 pp |
| Q4 2023 | 2023-12-31 | 2.06% | −0.67 pp |
| Q3 2023 | 2023-09-30 | −20.23% | +64.72 pp |
| Q2 2023 | 2023-06-30 | −24.55% | +20.70 pp |
| Q1 2023 | 2023-03-31 | −51.92% | +112.08 pp |
| Q4 2022 | 2022-12-31 | 2.73% | +113.67 pp |
| Q3 2022 | 2022-09-30 | −84.95% | +12.31 pp |
| Q2 2022 | 2022-06-30 | −45.25% | +7.37 pp |
| Q1 2022 | 2022-03-31 | −164.00% | −212.75 pp |
| Q4 2021 | 2021-12-31 | −110.94% | −6.67 pp |
| Q3 2021 | 2021-09-30 | −97.26% | −20.18 pp |
| Q2 2021 | 2021-06-30 | −52.62% | +57.09 pp |
| Q1 2021 | 2021-03-31 | 48.75% | +10.66 pp |
| Q4 2020 | 2020-12-31 | −104.27% | +7.42 pp |
| Q3 2020 | 2020-09-30 | −77.08% | −21.99 pp |
| Q2 2020 | 2020-06-30 | −109.71% | +88.30 pp |
| Q1 2020 | 2020-03-31 | 38.10% | +177.50 pp |
| Q4 2019 | 2019-12-31 | −111.69% | −120.22 pp |
| Q3 2019 | 2019-09-30 | −55.09% | +433.42 pp |
| Q2 2019 | 2019-06-30 | −198.00% | +1232.16 pp |
| Q1 2019 | 2019-03-31 | −139.40% | — |
| Q4 2018 | 2018-12-31 | 8.53% | — |
| Q3 2018 | 2018-09-30 | −488.51% | +1473.71 pp |
| Q2 2018 | 2018-06-30 | −1,430.16% | — |
| Q3 2017 | 2017-09-30 | −1,962.22% | −1360.39 pp |
| Q1 2017 | 2017-03-31 | −427.29% | — |
| Q3 2016 | 2016-09-30 | −601.84% | — |
| Q2 2011 | 2011-06-30 | −5,436.46% | −5491.11 pp |
| Q2 2010 | 2010-06-30 | 54.65% | — |
Rigel Pharmaceuticals net profit margin trends
Over the last five fiscal years, Rigel Pharmaceuticals's net profit margin increased from −27.38% to 124.72%, a change of +152.10 percentage points. The latest reported quarter, Q2 2026, shows 21.97%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rigel Pharmaceuticals source filings ↗